Susan McLellan, MD, MPH, FIDSA, FASTMH

Dr. McLellan is Professor of Medicine in the Infectious Diseases Division at UTMB, Medical Director of the Biocontainment Treatment Unit, and Director of Biosafety for Research-related Infectious Pathogens and of SPECTRE, the Special Pathogens Excellence in Clinical Treatment, Readiness, and Education Program. Board certified in Internal Medicine, Pediatrics, and Infectious Diseases, she has over 25 years of experience in medical and public health education and in the clinical care of and public health response to emerging infectious diseases. Her interests include travel and tropical medicine, the delivery of medical care in resource-poor areas, and the delivery of care and research in biocontainment settings as well as general infectious diseases and HIV. She has participated in outbreak and disaster response in various resource-poor settings, including as a clinical consultant for WHO during the West Africa and DRC Ebola outbreaks, providing direct care as well as assessment of treatment units and support of clinical trials of medical therapies. In her position at UTMB her focus is on improving the clinical care of individuals infected with high containment pathogens in both high and low resource settings. In 2020 she created the SPECTRE Program, which supports preparedness for the care of special pathogens across a 5 state region and integrates with the developing National Special Pathogens System of Care (NSPS). She serves as lead for all activities associated with UTMB’s Regional Emerging Special Pathogens Treatment Center and has been PI for several clinical research protocols including an infectious diseases biorepository and trials of medical countermeasures for emerging infectious diseases.
Financial relationships
-
Attribution:SelfNature of financial relationship:StockIneligible company:PfizerDate added:04/01/2025Date updated:04/01/2025
-
Attribution:SelfNature of financial relationship:StockIneligible company:AbbottDate added:04/01/2025Date updated:04/01/2025
-
Attribution:SelfNature of financial relationship:StockIneligible company:GileadDate added:04/01/2025Date updated:04/01/2025